In this second of two fall reports on treatment development for Duchenne muscular dystrophy, news about ARM210, CAP-1002, PDE5 inhibitors, drisapersen and CAT-1004 is presented
posted on December 4, 2014 - 3:13pm
Update (Feb. 6, 2015): This article has been amended to show that Catabasis' compound CAT-1004 is expected to move into clinical testing in boys with DMD during the first half of 2015.
MDA awarded $120,000 to Catabasis Pharmaceuticals to test two anti-inflammatory compounds, CAT-1004 and CAT-1040, in the mdx mouse model of Duchenne MD
posted on April 4, 2012 - 5:30am
The Muscular Dystrophy Association has awarded $120,000 to Cambridge, Mass.-based Catabasis Pharmaceuticals as part of a strategic partnership under which the pharmaceuticals company will test two compounds called CAT-1004 and CAT-1040 in the mdx research mouse model of Duchenne muscular dystrophy (DMD).